Among the new biomarkers to propose therapeutic decisions in patients suffering from multiple sclerosis (MS) are the IgM oligoclonal bands (OCBs) in cerebrospinal fluid (CSF). At the current time, however, IgM OCBs are detected in laboratories at investigation level and not in the routine practice due to their complexity. For this, we have applied a semi-automated method based on an isoelectrofocusing platform from Sebia of wide availability in clinical laboratories. The IgM OCBs results were validated in paired samples of CSF and serum from patients with MS previously carried out in a reference laboratory. We found a sensitivity of 91.67%, in agreement with previous data obtained with the reference method for IgM OCBs.

提议对患有多发性硬化症（MS）的患者进行治疗决策的新生物标记物是脑脊液（CSF）中的IgM寡克隆带（OCB）。但是，目前，由于IgM OCB的复杂性，它们在实验室处于调查级别而不是常规实践中。为此，我们应用了基于来自塞尔维亚的等电聚焦平台的半自动化方法，该方法在临床实验室中具有广泛的可用性。IgM OCBs结果在先前在参考实验室中进行过的MS患者的CSF和血清配对样品中得到了验证。我们发现灵敏度为91.67％，与之前使用IgM OCB的参考方法获得的数据相符。